Related Experiment Video

Updated: Jul 11, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance

G A Kaysen1

  • 1Division of Nephrology, Department of Medicine, University of California, Davis, California 95616, USA. gakaysen@ucdavis.edu

Kidney International
|September 21, 2007
PubMed

Insights

Chronic kidney disease (CKD) causes abnormal lipid profiles, increasing triglyceride-rich lipoproteins (TRLPs) due to impaired clearance. This dyslipidemia elevates vascular disease risk in dialysis patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Chronic kidney disease (CKD) is linked to dyslipidemia, marked by elevated triglyceride-rich lipoproteins (TRLPs) like very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL).
  • Low high-density lipoprotein (HDL) and unchanged or reduced low-density lipoprotein (LDL) levels are also characteristic of CKD-associated dyslipidemia.
  • Serum triglycerides and IDL are identified as significant risk factors for vascular disease in patients undergoing dialysis, unlike LDL.

Discussion:

  • The primary driver of increased TRLPs in CKD is reduced clearance, not enhanced synthesis.
  • Impaired lipoprotein clearance stems from diminished lipoprotein receptor expression, decreased lipase activity, and elevated levels of inhibitory low-molecular weight apolipoproteins.
  • Very low-density lipoprotein (VLDL) in dialysis patients exhibits structural abnormalities, leading to inefficient metabolism by lipoprotein lipase (LPL).

Key Insights:

  • Dyslipidemia in CKD involves a complex interplay of reduced lipoprotein catabolism and altered lipoprotein structure.
  • Vascular disease risk in dialysis patients is significantly associated with elevated triglycerides and IDL levels.
  • Therapeutic strategies may need to focus on enhancing lipoprotein clearance mechanisms in CKD patients.

Outlook:

  • Further research into the specific mechanisms of impaired lipoprotein clearance in CKD is warranted.
  • Developing targeted interventions to improve TRLP metabolism could mitigate cardiovascular risks in dialysis patients.
  • Understanding the structural-functional relationship of VLDL in CKD may reveal novel therapeutic targets.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...